VAXX Stock Overview
A biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vaxxinity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.000001 |
| Beta | 1.07 |
| 11 Month Change | -90.00% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.98% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| VAXX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 2.2% |
| 1Y | -100.0% | 16.2% | 31.7% |
Return vs Industry: VAXX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: VAXX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| VAXX volatility | |
|---|---|
| VAXX Average Weekly Movement | 11,290.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VAXX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VAXX's weekly volatility has increased from 5750% to 11291% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 61 | Mei Hu | www.vaxxinity.com |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial.
Vaxxinity, Inc. Fundamentals Summary
| VAXX fundamental statistics | |
|---|---|
| Market cap | US$25.35k |
| Earnings (TTM) | -US$56.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VAXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAXX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.93m |
| Earnings | -US$56.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 113.1% |
How did VAXX perform over the long term?
See historical performance and comparison